io SOLUTIONS

io CT/NG


Undergoing a pivotal 510(k) clinical study

The binx health io CT/NG test, designed to be performed in the clinic or decentralized laboratory while the patient waits, can enable immediate treatment of positive patients, removing the need for presumptive treatment, improving compliance, and reducing loss to follow-up.

Rapid test results provided by the io CT/NG assist in lowering the risk of onward transmission of these STIs and the potential for sequelae in infected patients, whilst reducing clinical pathway costs and improving the patient experience. The use of two discrete NG targets provides simultaneous confirmatory testing for greater accuracy and confidence.

* FOR INVESTIGATIONAL USE ONLY. NOT FOR SALE IN THE UNITED STATES.

io SOLUTIONS

io MSTI+

The binx health io MSTI+ (Multi-STI+) test is a combined test for four common sexually transmitted diseases, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, infections with similar symptoms but requiring different treatments.

The iO MSTI+ Cartridge is being developed to enable the detection and identification of these four STI pathogens in about 30 minutes from a single patient specimen, with a goal of expediting targeted therapy, thereby reducing inappropriate and presumptive treatment, and improving antibiotic stewardship.

* FOR INVESTIGATIONAL USE ONLY. NOT FOR SALE IN THE UNITED STATES.

io SOLUTIONS

io MG+R

The io MG+R test is being developed to simultaneously detect the presence of Mycoplasma genitalium and mutations associated with macrolide resistance which we believe will enable immediate and effective treatment of Mycoplasma genitalium positive patients with the appropriate antibiotic, to ensure better antibiotic stewardship and lower treatment costs for many patients.

* FOR INVESTIGATIONAL USE ONLY. NOT FOR SALE IN THE UNITED STATES.